ASSEMBLY BIOSCIENCES, INC.
ASMB evidence brief
What we can confirm
- BioSniper Score:
- 7.6 / 10
- Market Cap:
- $620.2M
- Lead Asset:
- abi-1179 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ASMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASMB
Assembly Biosciences is a biotechnology company developing oral small-molecule therapeutics for serious viral and liver diseases, with lead programs in recurrent genital herpes (helicase-primase inhibitors partnered with Gilead) and chronic hepatitis delta virus (entry inhibitor ABI-6250).
Key risk: Clinical development risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$620.2M
Cash Runway
—
Lead Asset
abi-1179 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 5 clinical trials for ASSEMBLY BIOSCIENCES, INC..
Assembly Biosciences is a biotechnology company developing oral small-molecule therapeutics for serious viral and liver diseases, with lead programs in recurrent genital herpes (helicase-primase inhibitors partnered with Gilead) and chronic hepatitis delta virus (entry inhibitor ABI-6250).
- Cash & equivalents of $32.3M as of 2026-06-30 [sec].
- Total revenue of $13.4M and net loss of -$3.9M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $305.6M as of 2026-06-30 [sec].
- Completed $115 million gross financing to support pipeline advancement [news · 2026-08-13].
- Cash runway projected into 2029, including a $75 million Gilead collaboration extension fee payable in Q4 2026 [news · 2026-09-08].
What works
- Gilead exercised a U.S. profit-share option for the HSV helicase-primase inhibitor program, with Assembly Bio sharing 40% of U.S. development costs and profits [news · 2026-09-08].
- ABI-6250 clinical development expanded into cholestatic liver diseases (PBC and PSC), broadening its potential market beyond chronic HDV [news · 2026-08-13].
- GS-1179 (formerly ABI-1179) selected to advance in the HSV HPI program, with Phase 2 initiation expected by year-end 2026 [news · 2026-08-13].
- Cash runway projected into 2029, providing extended financial visibility [news · 2026-09-08].
What to weigh
- Net loss of -$3.9M for the six months ended 2026-06-30 indicates ongoing operating losses [sec].
- ABI-6250 faces competition from at least two other Phase 2 candidates for chronic HDV (Bluejay Therapeutics' brelovitug and Gilead's GS-4321) [pipeline].
- The HSV helicase-primase program is still in Phase 1, with no approved product in that class yet [pipeline].
- Dependence on Gilead partnership for the HPI program; any change in collaboration terms could affect revenue and development [pipeline].
From the filings
Quoted directly from source documents.
Cash runway projected into 2029
“Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026”
News · September 8, 2026
Gilead profit-share option exercised for HSV HPI program
“Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes”
News · September 8, 2026
ABI-6250 Phase 2 initiation in cholestatic liver diseases expected Q1 2027
“Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027”
News · May 22, 2026
GS-1179 Phase 2 initiation expected by year-end 2026
“GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026”
News · August 13, 2026
Catalyst timeline
- 2026-10-01 · Phase 2 start for ABI-6250 — A Phase 2, multicenter, open-label, parallel-group study of ABI-6250 in patients with chronic hepatitis delta virus infection.
Risks & what to watch (4)›
Key risks
- Clinical development risk — All pipeline candidates are in Phase 1 or Phase 2; no approved products yet. Failure in trials could halt programs [pipeline].
- Competition in HDV — ABI-6250 faces two Phase 2 competitors for chronic HDV: Bluejay Therapeutics' brelovitug and Gilead's GS-4321 [pipeline].
- Partnership dependency — The HSV HPI program is exclusively licensed to Gilead; Assembly Bio's revenue and development depend on Gilead's decisions [pipeline].
- Financial losses — Net loss of -$3.9M for the six months ended 2026-06-30; ongoing losses may require additional financing [sec].
What to watch
- Initiation of Phase 2 trial for GS-1179 in recurrent genital herpes by year-end 2026 [news · 2026-08-13].
- Initiation of Phase 2 trial for ABI-6250 in chronic HDV anticipated Q4 2026 [news · 2026-05-07].
- Initiation of Phase 2 study for ABI-6250 in PBC and PSC anticipated Q1 2027 [news · 2026-05-22].
- Receipt of $75 million Gilead collaboration extension fee in Q4 2026 [news · 2026-09-08].
Sources: Catalysts · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run ASSEMBLY BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ASSEMBLY BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08 · 0% dilution
Lead: Phase 2
7 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
75
Total value held
$380.3M
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 4,505,391 | $125.0M |
| farallon capital management llc | 1,227,590 | $34.1M |
| ra capital management, l.p. | 1,020,410 | $28.3M |
| commodore capital lp | 1,000,000 | $27.8M |
| janus henderson group plc | 849,309 | $23.5M |
| paradigm biocapital advisors lp | 665,251 | $18.5M |
| vanguard capital management llc | 490,447 | $13.6M |
| parkman healthcare partners llc | 411,227 | $11.4M |
| stempoint capital lp | 370,870 | $10.3M |
| point72 asset management, l.p. | 344,105 | $9.5M |
Showing top 10 of 75 institutional holders of ASSEMBLY BIOSCIENCES, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 14.4%
- Days to cover
- 15.9
- Shares short
- 1,557,158
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASMB short interestGovernance
Frequently asked questions
What is the AI investment thesis for ASSEMBLY BIOSCIENCES, INC.?
Assembly Biosciences is a biotechnology company developing oral small-molecule therapeutics for serious viral and liver diseases, with lead programs in recurrent genital herpes (helicase-primase inhibitors partnered with Gilead) and chronic hepatitis delta virus (entry inhibitor ABI-6250).
What is ASSEMBLY BIOSCIENCES, INC.'s lead drug candidate?
ASSEMBLY BIOSCIENCES, INC.'s most advanced tracked candidate is abi-1179 (Phase 1) for Recurrent Genital Herpes Simplex Type 2.
Who is the CEO of ASSEMBLY BIOSCIENCES, INC.?
Mr. Jason A. Okazaki J.D. is the chief executive officer of ASSEMBLY BIOSCIENCES, INC. (ASMB).
Where is ASSEMBLY BIOSCIENCES, INC. headquartered?
ASSEMBLY BIOSCIENCES, INC. (ASMB) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does ASSEMBLY BIOSCIENCES, INC. focus on?
ASSEMBLY BIOSCIENCES, INC. develops therapies across Oncology, Neurology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.